Suzanne Rivera named new VP for research

Provost W.A. "Bud" Baeslack III announced, on November 4th, the appointment of Suzanne M. Rivera as Case Western Reserve´s new vice president for research, effective this month. Rivera, the university´s associate vice president for research since January 2011, emerged as the top choice after an extensive process involving campuswide nominations of internal university candidates. Since coming to CWRU, Rivera has distinguished herself through a commitment to collaboration and a focus on systems and processes.
Read more about her.


Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
December 9, 2014  

Department of Defense

OFFICE OF STRATEGIC INITIATIVES - CALL FOR SUBMISSIONS

U.S. Army Medical Research and Materiel Command (USAMRMC) Broad Agency Announcement - BAA -15-1

Apply early. Funding is limited and subject to availability.
The BAA is continuously open, and accepts proposals on a rolling basis. Pre-proposals may be submitted and will be evaluated at any time throughout the year.

Scope: The USAMRMC's mission is to provide solutions to medical problems of importance to the American warfighter. Projects must pertain to at least one of the research areas of interest outlined in the BAA.

Funding: Budgets are not capped and must reflect the scope of the work. Funding can be requested for up to 5 years.

Areas of interest:
1. Military Infectious Diseases Research Program
2. Combat Casualty Care Research Program
3. Military Operational Medicine Research Program
4. Clinical and Rehabilitative Medicine Research Program
5. Medical Biological Defense Research Program
6. Medical Chemical Defense Research Program
7. Medical Simulation and Information Sciences Research Program 8. Radiation Health Effects Research Program
9. Special Investment Areas/Innovation Funding

Office of Strategic Initiatives (OSI): Case School of Medicine's OSI can work with you to make sure that you meet the current goals and objectives of the USAMRMC that is paramount for your success. OSI can assist you in preparing a competitive proposal and can help guide your efforts from the first draft of the pre-proposal to submission of the full application.

Timeline: Invitation to submit a Full proposal will be given within 90 days of submission of the pre-proposal. An additional 90 days is provided to the applicant to complete the full application. Allow for at least 6 months between submission of the whitepaper to submission of the full application.

Contact us: If you are planning on submitting a pre-proposal, have questions, or would like more information - contact OSI Project Manager Irene Shaland - ixs75@case.edu - 216.368.4970

 
Guidance for Transferring Research Materials and Data

All data and materials transferred into and outside of the institution require either a Material Transfer Agreement (MTA), a Data Use Agreement (DUA), or both. Material Transfer Agreements are used for the transfer of tangible materials (cell lines, mice, metallurgical samples, biological specimens), whereas Data Use Agreements are used for electronic or hardcopy data (including Protected Health Information, de-identified patient data, and non-human data).

All MTAs and DUAs should be routed through the Technology Transfer Office by sending a request to Andrew Jarrell at andrew.jarrell@case.edu.

 
The Cleveland Area Reliant IRB Review Process

The Cleveland Area Reliant Institutional Review Board (IRB) Review process includes participation by the Case Western Reserve University (CWRU) Social, Behavioral, and Educational Research (SBER) IRB, the Cleveland Clinic (CC) IRB, MetroHealth Medical Center (MHMC) IRB, and University Hospitals Case Medical Center (UHCMC) IRB. The process relies on executed IRB Authorization Agreements (IAA) between the institutions. These agreements document that all applicable human research subjects protection considerations will be made by one Institutional Review Board (IRB), which will be deemed the IRB of record. The IRBs of the other Cleveland area institutions will accept the approval of the IRB of record through the Reliant Review process. The goal is to eliminate duplication of effort and multiple applications for submission of the same protocol, and to encourage scientific collaboration among the affiliated institutions.

What types of studies are eligible for the Reliant Review Process?
Any type of human research study could be eligible for the Reliant Review process. These include but are not limited to investigator-initiated, federally-funded, foundation-supported, industry-sponsored, and non-funded studies.

The fundamental requirement is that a collaborating investigator must be named at each site where the research will occur. It is important for the Principal Investigator at the lead study site to work with the IRB of record throughout the Reliant Review Process to initiate acceptance of IRB approval at each collaborating site.

For further information, contact Kim Volarcik at (216) 368-0134 or kav6@case.edu.

 
J.M. Kaplan Fund

Through its Furthermore program, the J.M. Kaplan Fund supports nonfiction books about the urban experience; natural and historic resources; art, architecture, and design; cultural history; and civil liberties and other public issues.

The program seeks work that appeals to an informed general audience; demonstrates evidence of high standards in editing, design, and production; promises a reasonable shelf life; might not otherwise achieve top quality or even come into being; and "represents a contribution without which we would be the poorer."

Individual grants range from $500 to approximately $15,000 and may be used to support writing, research, editing, design, indexing, photography, illustration, and/or printing and binding.

See the Furthermore website for complete application guidelines and program information.

 
New Policy from NIH to Balance Sex in Cell and Animal Studies

NIH announced last week a new policy requiring "a balance of male and female cells and animals in preclinical studies in all future applications." In this week's Nature, Janine Clayton and Francis Collins write, "The over-reliance on male animals and cells in preclinical research obscures key sex differences that could guide clinical studies. And it might be harmful: women experience higher rates of adverse drug reactions than men do. Furthermore, inadequate inclusion of female cells and animals in experiments and inadequate analysis of data by sex may well contribute to the troubling rise of irreproducibility in preclinical biomedical research."

Read more at: http://ow.ly/wSqy6.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.